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Abstract
Background: The purpose of this study was to compare pre- and post-surgical healthcare costs in commercially
insured total joint arthroplasty (TJA) patients with osteoarthritis (OA) in the United States (U.S.).
Methods: Using a large healthcare claims database, we identified patients over age 39 with hip or knee OA who
underwent unilateral primary TJA (hip or knee) between 1/1/2006 and 9/30/2007. Utilization of healthcare services
and costs were aggregated into three periods: 12 months “pre-surgery,” 91 days “peri-operative,” and 3 to 15
month “follow-up,” Mean total pre-surgery costs were compared with follow-up costs using Wilcoxon signed-rank
test.
Results: 14,912 patients met inclusion criteria for the study. The mean total number of outpatient visits declined
from pre-surgery to follow-up (18.0 visits vs 17.1), while the percentage of patients hospitalized increased (from
7.5% to 9.8%) (both p < 0.01). Mean total costs during the follow-up period were 18% higher than during pre-
surgery ($11,043 vs. $9,632, p < 0.01), largely due to an increase in the costs of inpatient care associated with
hospital readmissions ($3,300 vs. $1,817, p < 0.01). Pharmacotherapy costs were similar for both periods ($2013
[follow-up] vs. $1922 [pre-surgery], p = 0.33); outpatient care costs were slightly lower in the follow-up period
($4338 vs. $4571, p < 0.01). Mean total costs for the peri-operative period were $36,553.
Conclusions: Mean total utilization of outpatient healthcare services declined slightly in the first year following TJA
(exclusive of the peri-operative period), while mean total healthcare costs increased during the same time period,
largely due to increased costs associated with hospital readmissions. Further study is necessary to determine
whether healthcare costs decrease in subsequent years.
Background
Advanced osteoarthritis (OA) of the hip and knee is asso-
ciated with severe pain, limitation in function, and
impaired quality of life [1,2]. Patients with advanced OA
of the hip or knee incur considerable healthcare costs
related to pain medications (both oral and injectable),
physical therapy, medical equipment, outpatient visits, and
inpatient care [3]. In addition, the indirect or so-called
“time costs” associated with lost productivity can be sub-
stantial [4]. Lower extremity (hip and knee) total joint
arthroplasty (total knee arthroplasty [TKA], total hip
arthroplasty [THA], collectively, TJA) has been associated
with alleviation of pain, improvement in function and
overall improvement in quality of life among patients with
disabling arthritis of the hip and knee [5]. However, little
is known about the economic impact of TJA on utilization
of healthcare services and total cost of care after recovery
from surgery in the United States. The purpose of this
study was to compare utilization of healthcare services
and direct healthcare costs in commercially insured TJA
patients during the pre- and post-surgical periods.
Methods
Data source
Data were obtained from the PharMetrics Patient-Centric
Database, which is comprised of facility, professional-ser-
vice, and retail (i.e., outpatient) pharmacy claims from over
85 health plans throughout the United States. These plans
provide health insurance to approximately 14 million peo-
ple annually (Midwest, 35%; Northeast, 21%; South, 31%;
West, 13%). All patient identifiers in the database are
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Health Insurance Portability and Accountability Act of
1996 (HIPAA). As no patiento rp r o v i d e rc o n t a c tw a s
made and patient information was de-identified, Institu-
tional Review Board (IRB) approval was not required.
Information available for each facility and professional-
service claim includes date and place of service, diagnoses
(in International Classifications of Diseases, 9
th Revision,
Clinical Modification [ICD-9-CM] format), procedures (in
ICD-9-CM [selected plans only], Current Procedural Ter-
minology, 4
th Edition [CPT-4], and Healthcare Common
Procedure Coding System [HCPCS] formats), provider
specialty, and charged and paid amounts. Data available
for each retail pharmacy claim include the drug dispensed
(in National Drug Code [NDC] format), the dispensing
date, and the quantity dispensed and number of days of
therapy supplied (selected plans only). All claims include a
charged amount; the database also provides paid (i.e.,
reimbursed, including patient deductible, copayment, and/
or coinsurance) amounts.
Selected demographic, clinical, and eligibility informa-
tion is also available, including age, gender, geographic
region, primary and secondary diagnoses, coverage type,
and the dates of insurance coverage. All patient-level data
can be arrayed chronologically to provide a detailed, longi-
tudinal profile of all medical and pharmacy services used
by each plan member. The database for this study encom-
passed the period, January 1, 2005 through December 31,
2008 ("study period”), which represented the most recent
period for which complete data were available at the point
of study initiation.
Study sample
The source population for this study consisted of all
patients with any claims for unilateral primary TKR (CPT-
4 code 27447 or ICD-9-CM procedure code 81.54) or uni-
lateral primary THR (CPT-4 code 27130 or ICD-9-CM
procedure code 81.51) between January 1, 2006 and Sep-
tember 30, 2007. (Patients undergoing partial or revision
hip or knee replacements were excluded from the analy-
sis). Among these patients, the date of the first-noted
claim for TKR or THR was designated the “index proce-
dure date”, and patients not continuously enrolled in the
database for the 12 month period prior to this date (“pre-
surgery period”) and the 15-month period subsequent to
this date (“post-operative period”) were excluded from the
study sample.
Patients without diagnoses of OA (ICD-9-CM diagnosis
codes 715.X5, 715.X6) in the three-month period preced-
ing surgery were excluded from the study sample, as were
those aged less than 40 years as of the time of their index
procedure, those enrolled in Medicaid, and persons aged
65 years and older as of the time of their index procedure
who were enrolled in a Medicare Advantage plan (because
their claims histories are incomplete in the study data-
base). Additional exclusions from the study sample
included persons with evidence of any of the following
during the one-year pre-surgery period: (1) prior TKR or
THR; (2) joint fusion (CPT-4 27284, 27286, 27580); (3)
procedures suggestive of a prior TKR/THR (CPT-4 codes
27090, 27091, 27134, 27137, 27138, 27488, 27486, 27487);
(4) knee or hip fracture (ICD-9-CM diagnosis codes 820.
XX, 821.2, 821.3, 823.0, 823.1) (in 30-day period prior to
index procedure date only); (5) other conditions associated
with TKR/THR (e.g., rheumatoid arthritis (ICD-9-CM
codes 714, 714.X), post-traumatic arthritis (716.15,
716.16), avascular necrosis (733.42, 733.43) benign/malig-
nant bone tumors (170.7, 213.7), or Paget’s disease (731.0)
during the pre-surgery period, and (6) patients who under-
went a second primary TKA or THA during the 15-month
period subsequent to the index procedure date
a. All phar-
macy, professional service, and facility claims were then
compiled for all patients in the study sample over the one-
year pre-surgery period and the 15-month post-operative
period.
Measures and analyses
The demographic and clinical characteristics of study
subjects were examined, including prevalence of selected
comorbidities, on the basis of information prior to the
index procedure date. Patients were assumed to have a
particular comorbidity if they had either one or more
hospitalizations, or two or more outpatient claims at
least 30 days apart, during the pre-surgery period with a
corresponding diagnosis code/prescription.
Total healthcare costs were aggregated into three dis-
tinct periods: pre-surgery period (12-months prior to
TJA); “peri-operative” (91-day period including and imme-
diately following TJA); and “follow-up” (12-month period
following the peri-operative period). Healthcare costs over
each period were subcategorized into (1) pharmacotherapy
(including oral, injectable, and topical agents); (2) outpati-
ent care (including physician visits, other outpatient office
visits [including but not necessarily limited to physical/
occupational therapists), Emergency Department (ED) vis-
its, and diagnostic imaging)]; (3) inpatient care; and (4) all
other costs. Pharmacotherapy was further subcategorized
as: (1) nonsteroidal anti-inflammatory drugs (NSAIDs),
including cyclo-oxygenase (COX)-2 selective NSAIDs; (2)
opioids, including tramadol; (3) antidepressants; (4) intra-
articular corticosteroid and hyaluronic acid injections; and
(5) all other medications.
Reimbursed amounts (i.e., payments made by third-
party insurers as well as any patient liability [e.g., co-pays,
co-insurance]) were used in all analyses of healthcare
costs. All costs were expressed on an “as-is” basis (i.e.,
costs were not adjusted for inflation). Non-parametric
bootstrapping (using sampling [with replacement] from
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dence intervals (CIs) for all estimates of healthcare costs
[6]. All estimates of cost were generated on a “per-
patient” basis (e.g., total mean per-patient healthcare
costs).
Mean total pre-surgery costs—for each sub-category and
in aggregate—were compared with follow-up costs using
Wilcoxon signed-rank tests; the percentages of patients
with ≥1 hospitalizations during the pre-surgery versus
follow-up periods were compared using McNemar’s test.
Utilization of healthcare services and costs occurring dur-
ing the 90-day peri-operative period were excluded from
analyses comparing pre-surgery with follow-up so as to
compare healthcare costs and healthcare services utiliza-
tion during the 1-year period prior to TJA with those of
the 1-year period following recovery from TJA. (Levels of
healthcare services utilization and costs during the peri-
operative period were tabulated and reported separately.)
Results
A total of 14,912 met the inclusion criteria for the study.
The mean age of patients included in the study was 57.3
years, and 57% were women; approximately 17% of
patients in our sample were 65 years of age or older
(Table 1). All geographic regions of the country were
represented, with the largest number of patients from the
Midwest (41.9%), and the least number of patients from
the West (13.5%). The most common comorbidities were
hypertension (60.1%), hyperlipidemia (55.3%), and back
pain (29.5%). Fifty-five percent of patients were enrolled in
Preferred Provider Organizations (PPO), 24% were
enrolled in Health Maintenance Organizations (HMO),
and 16% were enrolled in Point of Service (POS) plans.
Prescriptions for NSAIDs and opioids declined slightly
during the follow-up period relative to the pre-surgery
period (mean [SD] per-patient number of NSAID pre-
scriptions = 2.0 [3.4] for pre-surgery vs 1.4 [2.9] for fol-
low-up; for opioids, it was 2.5 [5.2] vs. 2.2 [5.4] [both p <
0.01]) (Table 2). Utilization of outpatient healthcare ser-
vices, as measured by the number of outpatient visits, also
declined slightly during the follow-up period. ED visits
were unchanged between the two periods (mean [SD] per-
patient value = 0.2 [0.7] for pre-surgery vs. 0.2 [0.9] for
follow-up; p = 0.61)., Importantly, the percentage of
patients with ≥1 hospitalizations increased (from 7.5% dur-
ing pre-surgery to 9.8% during follow-up; p < 0.01).
Mean total per-patient healthcare costs during the fol-
low-up period were 18% higher than during the pre-sur-
gery period ($11,043 vs. $9,632, p < 0.01) (Table 3).
Mean total per-patient costs for the 90-day peri-opera-
tive period (including those related to hospitalization for
the index procedure) were $36,553. Per-patient pharma-
cotherapy costs were similar for both the follow-up and
pre-surgery periods ($2013 [follow-up] vs. $1922 [pre-
surgery], p = 0.33).
However, within pharmacotherapy, mean total per-
patient follow-up costs were lower than mean total pre-
surgery costs for NSAIDs ($98 vs. $15, p <0 . 0 1 )a n d
injectable agents ($18 vs. $107, p < 0.01), but higher for
Table 1 Demographic and clinical characteristics of study
subjects (N = 14,912)
Characteristic Mean (%)
Mean Age (SD) 57.3 (7.3)
Gender (N,%)
Male 6,417 (43.0%)
Female 8,495 (57.0%)
Comorbidity
Hypertension 8,957 (60.1)
Hyperlipidemia 8,252 (55.3)
Neoplasms 4,522 (30.3)
Back pain 4,398 (29.5)
Painful neuropathic disorders 4,363 (29.3)
Chest pain 3,568 (23.9)
Diabetes 2,867 (19.2)
Fatigue 2,754(18.5)
Abdominal pain 2,678 (18)
Depressive disorders 2,160 (14.5)
Obesity 2,053 (13.8)
Sleep disorders 2,041 (13.7)
Ischemic heart disease 2,015 (13.5)
Cervical pain 1,687 (11.3)
Cardiac dysrythmias 1,612 (10.8)
Fibromyalgia 1,414 (9.5)
Anxiety disorders 1,302 (8.7)
Headache 1,298 (8.7)
Valve disease 1,158 (7.8)
Cerebrovascular disease 651 (4.4)
Migraine 530 (3.6)
Gout 479 (3.2)
Congestive heart failure 422 (2.8)
Payer Type
HMO 3,546 (23.8)
PPO 8,169 (54.8)
POS 2,356 (15.8)
Other/unknown 622 (4.2)
Census Region
Northeast 4,322 (29.0)
South 2,332 (15.6)
Midwest 6,250 (41.9)
West 2,008 (13.5)
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vs. $146, p < 0.01), and all other medications ($1550 vs.
$1358, p < 0.01). On a per-patient basis, outpatient care
costs were slightly lower in the follow-up period than in
the pre-surgery period ($4338 vs. $4571, p < 0.01),
whereas mean per-patient inpatient costs were substan-
tially higher in the follow-up period when compared
with the pre-surgery period ($3300 vs. $1817, p < 0.01).
All other per-patient healthcare costs were also slightly
higher in the follow-up period ($1392 vs. $1323,
p < 0.01).
Discussion
The economic burden of osteoarthritis has been increas-
ing in the United States, in part due to an increase in the
prevalence of disease, and to increasing costs of treat-
ment (both surgical and non-surgical) [7,8]. At the same
time, concerns have been raised regarding the costs asso-
ciated with TJA, due to an increase in the number of pro-
cedures performed annually in the U.S., management of
post-surgical complications, and increased adoption of
newer, more expensive implant technologies [9]. TJA has
been shown to be a cost-effective intervention relative to
non-operative treatment [10-13] and has been associated
with dramatic improvements in quality of life in patients
who suffer from debilitating OA of the hip and knee
[5,14,15]. Several investigators have shown that when
performed in younger patients, TJA can expedite return
to work and a more active, productive lifestyle [16,17].
While previous authors have reported that OA is asso-
ciated with substantial direct and indirect medical expen-
ditures [6,16,17], relatively little is known about the direct
medical costs before and after hip and knee arthroplasty in
patients with OA. Hawker and colleagues undertook a
nested case-control study to examine total and arthritis-
attributable costs in the periods before and after TJA
among persons with disabling arthritis of the hip and/or
knee in Ontario, Canada [18]. The pre-surgery period was
defined as the 1-year period ending 6 weeks prior to TJA;
the peri-operative period, as beginning 6 weeks prior to
Table 2 Levels of utilization of healthcare services during pre-surgery, peri-operative, and follow-up periods among
study subjects (N = 14,912)*
Period Period Period
Pre-surgery Peri-operative Follow-up p-value**
Prescriptions
Pain-related
Oral medications
NSAIDs
† 2.0 (3.4) 0.4 (0.9) 1.4 (2.9) < 0.01
Opioids 2.5 (5.2) 3.0 (3.1) 2.2 (5.4) < 0.01
Antiepileptics 0.5 (2.2) 0.1 (0.6) 0.6 (2.6) < 0.01
Antidepressants
‡ 1.6 (4.1) 0.4 (1.1) 1.9 (4.5) < 0.01
Injectable agents
Corticosteroids 0.9 (1.6) 0.1 (0.6) 0.5 (1.3) < 0.01
Opioids 0.1 (0.6) 0.0 (0.3) 0.1 (0.6) 0.13
Hyaluronic acid 0.4 (1.5) 0.0 (0.1) 0.0 (0.4) < 0.01
Total of above 1.4 (2.5) 0.1 (0.7) 0.6 (1.6) < 0.01
Topical agents 0.1 (0.4) 0.0 (0.1) 0.1 (0.5) < 0.01
Total number of prescriptions 7.1 (7.1) 9.2 (15.2) 10.7 (15.2) < 0.01
Healthcare services
Outpatient care
Physician office visits 15.9 (13.3) 12.0 (9.7) 15.3 (15.0) < 0.01
Other outpatient visits 3.2 (4.7) 2.7 (4.9) 2.6 (5.1) < 0.01
ED visits 0.2 (0.7) 0.1 (0.4) 0.2 (0.9) 0.61
All outpatient visits 18.0 (14.3) 14.2 (9.6) 17.1 (16.1) < 0.01
Hospitalizations
No. (%) with ≥ 1 hospitalizations 1,115 (7.5) 14,392 (96.5) 1,456 (9.8) < 0.01
*Unless otherwise noted, all values are per-patient mean (SD)
**Pre-surgery vs follow-up
†Includes acetaminophen
‡Comprised of tricyclic antidepressants, selective serotonin reuptake inhibitors, bupropion, buspirone, duloxetine, maprotiline, mirtazapine, nefazodone, and
venlafaxine
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surgery period, the 1-year period thereafter. The authors
found that while mean arthritis-attributable costs during
post-surgery decreased from pre-surgery levels by $278
(Canadian dollars, expressed in calendar-year [CY] costs),
total healthcare costs increased by $1978. In their analyses
of total healthcare costs of patients who underwent TJA
for any reason (exclusive of bone cancers) during the 3-
year periods immediately before and after surgery, Graver
et al. [19] reported total healthcare costs of $8762,
$10,076, and $11,475 in the third, second, and year imme-
diately prior to TJA, respectively; corresponding values for
the 3 years immediately following and including the
surgery were $37,445, $11,980, and $11,307. While Graver
and colleagues did not account for the peri-operative per-
iod, which render direct comparisons between their work
and ours somewhat difficult, we note that their reported
costs in the second year subsequent to TJA are higher
than those reported in the year prior to surgery (statistical
significance testing not undertaken).
Our results indicate that although utilization of health-
care services decreased for most services during the first
year following TJA (exclusive of the peri-operative per-
iod) in commercially insured patients with OA of the hip
or knee, mean total healthcare costs increased, largely
due to increased costs associated with inpatient care.
Table 3 Mean per-patient healthcare costs during pre-surgery, peri-operative, and follow-up periods among study
subjects (N = 14,912)*
Period
Pre-surgery Peri-operative Follow-up p-value**
Prescriptions
Pain-related
Oral medications
NSAIDs
† 153 (147, 158) 28 (26, 29) 98 (93, 103) < 0.01
Opioids 97 (79, 116) 60 (56, 64) 110 (83, 137) < 0.01
Antiepileptics 58 (52, 64) 15 (13, 17) 77 (66, 87) < 0.01
Antidepressants
‡ 146 (138, 154) 35 (33, 37) 154 (146, 162) < 0.01
Corticosteroids 2 (2, 2) 0 (0, 1) 2 (2, 3) 0.16
Injectable agents
Corticosteroids 15 (12, 18) 4 (2, 6) 10 (6, 13) < 0.01
Opioids 2 (2, 2) 1 (1, 1) 2 (2, 2) 0.09
Hyaluronic acid 90 (84, 95) 1 (1, 1) 6 (5, 8) < 0.01
Total of above 107 (101, 113) 6 (4, 8) 18 (15, 22) < 0.01
Topical agents 2 (1, 2) 0 (0, 1) 4 (3, 5) < 0.01
All other 1,358 (1,318, 1,389) 459 (447, 471) 1,550 (1,506, 1,594) < 0.01
Total Pharmacotherapy 1,922 (1,870, 1,974) 604 (589, 619) 2,013 (1,954, 2,072) 0.33
Healthcare services
Outpatient care
Physician office visits 2,364 (2,320, 2,408) 1,410 (1,383, 1,437) 2,148 (2,096, 2,199) < 0.01
Other outpatient visits 2, 024 (1,901, 2,148) 1,978 (1,844, 2,111) 1,980 (1,812, 2,148) < 0.01
ED visits 183 (169, 197) 96 (87, 105) 211 (195, 227) 0.06
All outpatient visits 4,571 (4,429, 4,714) 3,484 (3,345, 3,622) 4,338 (4,149, 4,528) < 0.01
Inpatient care 1,817 (1,655, 1,979) 31,116 (30,802, 31,431) 3,300 (3,007, 3,593) < 0.01
Other
OA-related
¥ 30 (27, 33) 48 (46, 50) 13 (11, 15) < 0.01
All other 1,293 (1,229, 1,356) 1,300 (1,248, 1,353) 1,379 (1,297, 1,461) < 0.01
Total 9,632 (9,364, 9,901) 36,553 (36,221, 36,885) 11,043 (10,628, 11,458) < 0.01
*Unless otherwise noted, all values are mean (95% confidence interval) per-patient healthcare costs ($)
**Pre-surgery vs follow-up
†Includes acetaminophen
‡Comprised of tricyclic antidepressants, selective serotonin reuptake inhibitors, bupropion, buspirone, duloxetine, maprotiline, mirtazapine, nefazodone, and
venlafaxine
¥Medical equipment
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tive period (a 3-month “window” that includes the admis-
sion for the initial TJA as well as any subsequent
readmission) was only 6.9 days, and that 75% of patients
spent no more than 8 days in hospital during this time,
our findings are most likely associated with readmissions,
rather than stays in hospital for the initial TJA of > 91
days. Hospital readmissions following elective surgical
procedures such as TJA have become the focus of great
debate and concern among healthcare policymakers [20],
and have led to calls for changes in payment policy to
incentivize better coordination of post-discharge care
among providers [21,22]. Based on our findings, further
investigation is warranted into the cause of and strategies
to decrease the rate of hospital readmissions following
elective TJA.
Despite the interesting findings, our study has several
limitations. First, our database consisted of administra-
tive claims for patients enrolled in private insurance
plans, who tend on average to be younger than the
“typical” cohort who undergoes TJA for OA. Specifically,
while patients aged ≥65 years comprise approximately
two-thirds of all patients who undergo TJA in the US
[23], they only represented about 17% of patients in our
sample. However, we would note that as the indications
for TJA have expanded to include younger, more active
patients, an increasing number of patients under the age
of 65 are undergoing TJA [24].
Second, our analysis relied upon administrative claims
data, which have been shown to have an imperfect cor-
relation with the clinical record [25]. It is possible that
certain costs may have been over- or under-estimated in
both the pre-surgery and follow-up period due to the
reliance on administrative claims data. However, we
believe that the majority of healthcare costs experienced
by patients in the periods immediately before and after
TJA are captured within the database. Because the prin-
cipal purpose of administrative databases such as the
one we used in this study are to support reimbursement,
we believe that our study yields a fairly comprehensive
view of “real-world” utilization and cost of healthcare
services in commercially insured patients who undergo
TJA.
Third, and somewhat related to the second, we did
not attempt to adjust for price inflation by expressing
costs in terms of a particular “base year”.T h ep r i n c i p a l
reason that we did not undertake such an adjustment
was that we thought it important to examine (and
report) actual amounts paid in “real-word” clinical prac-
tice during the periods before and after joint replace-
ment. Were we to have expressed all costs in terms of a
“base year”, such information would not be available.
We also note that identification of an appropriate “price
index” to adjust healthcare costs is not straightforward.
In most instances where this method is employed, a sin-
gle index (e.g., the medical-care component of the US
consumer price index) is used to adjust values; implicit
in use of this single index, however, is the assumption
that all goods and services (e.g., pharmacotherapy, phy-
sician office visits, hospitalizations, durable medical
equipment) experience the same relative change in pri-
cing in a given year. The degree to which that assump-
tion is valid within any given year is unknown.
Regardless, to the extent that differences between pre-
treatment and follow-up costs reflect price inflation, our
findings may overestimate differences in healthcare costs
between these two periods.
Fourth, although recovery from TJA surgery is vari-
able, it is possible that some patients were not fully
recovered from surgery by 90 days [26], and therefore
some of the costs included in the follow-up period may
have been related to recovery from TJA. The 90-day
window for the peri-operative period chosen because
this is considered the ‘global period’ by most insurers,
during which time all costs that are incurred are consid-
ered attributable to the index procedure. This limitation
is further mitigated by the fact that the major difference
in costs between the pre-surgery and follow-up period
was related to inpatient care, and it is unlikely that
these costs would be considered routine follow-up costs.
Since our goal was to evaluate the impact of TJA on
healthcare resource utilization and total direct health-
care spending during the first 15 months following sur-
gery from a healthcare system perspective, we did not
attempt to separate out costs that were directly attribu-
table to OA or TJA, which may account for the differ-
ence in our findings from those of Hawker, et al. [18]
Additionally, we were unable to include indirect or time
costs in our analysis, and it is quite possible that the
increase in direct medical costs during the follow-up
period could be offset by reductions in indirect or time
costs associated with earlier return to work and
increased productivity, especially given the relatively
young average age (57.3 years) of the commercially
insured patients who were included in our study. Addi-
tionally, we only measured costs during the 15 months
immediately following the index TJA procedure, while
the benefits of TJA are known to accrue over many
years and in some cases decades. Nonetheless, it is
anticipated that most patients (especially the younger
patients included in this study) recover completely from
surgery within 3 months, and therefore, their use of
healthcare services and the associated costs would be
expected to decrease after that time.
Conclusions
In summary, despite slightly lower outpatient care costs
and similar costs associated with pharmacotherapy, we
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during the 12-month period following recovery from
TJA when compared with the 12-month period prior to
surgery in commercially insured patients with OA, in
large part due to increased costs associated with hospital
readmissions. Further study is necessary to determine
whether healthcare costs decrease in subsequent years.
Endnotes
aPatients who underwent a second primary TKA or
THA during the 15-month period subsequent to the
index procedure were excluded, as these procedures are
often scheduled electively following recovery from the
index procedure, they are not indicative or reflective of
the condition of the index joint, and they substantially
impact the cost and utilization of healthcare services
during the time period under study.
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